FEBS Letters | |
Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals | |
Hermann, Marcela4  Seelos, Christian1  Held, Irmtraud3  Exner, Markus2  Gmeiner, Bernhard3  Hofbauer, Roland2  Kapiotis, Stylianos2  | |
[1] Institute of Tumorbiology, University of Vienna, Vienna, Austria;Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Vienna, Austria;Institute of Medical Chemistry, University of Vienna, Währingerstr. 10, A-1090 Vienna, Austria;From the Institute of Molecular Genetics, University of Vienna, Vienna, Austria | |
关键词: LDL oxidation; Superoxide; Nitric oxide; Antioxidant; Aspirin; Salicylate; SIN-1; | |
DOI : 10.1016/S0014-5793(99)00043-5 | |
学科分类:生物化学/生物物理 | |
来源: John Wiley & Sons Ltd. | |
【 摘 要 】
Simultaneously produced superoxide/nitric oxide radicals (O⋅− 2/NO⋅) could form peroxynitrite (OONO−) which has been found to cause atherogenic, i.e. oxidative modification of LDL. Aromatic hydroxylation and nitration of the aspirin metabolite salicylate by OONO− has been reported. Therefore we tested if salicylate may be able to protect LDL from oxidation by O⋅− 2/NO⋅ by scavenging the OONO− reactive decomposition products. When LDL was exposed to simultaneously produced O⋅− 2/NO⋅ using the sydnonimine SIN-1, salicylate exerted an inhibitory effect on LDL oxidation as measured by TBARS and lipid hydroperoxide formation and alteration in electrophoretic mobility of LDL. The cytotoxic effect of SIN-1 pre-oxidised LDL to endothelial cells was also diminished when salicylate was present during SIN-1 treatment of LDL. Spectrophotometric analysis revealed that salicylate was converted to dihydroxybenzoic acid (DHBA) derivatives in the presence of SIN-1. 2,3- and 2,5-DHBA were even more effective to protect LDL from oxidation by O⋅− 2/NO⋅. Because O⋅− 2/NO⋅ can occur in vivo, the results may indicate that salicylate could act as an efficacious inhibitor of O⋅− 2/NO⋅ initiated atherogenic LDL modification, thus further supporting the rationale of aspirin medication regarding cardiovascular diseases.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912020307301ZK.pdf | 98KB | download |